
March 19 (Reuters) - Paratek Pharmaceuticals:
PARATEK PHARMACEUTICALS TO ACQUIRE OPTINOSE, CREATING SIGNIFICANT COMMERCIAL EXPANSION OPPORTUNITIES FOR XHANCE® IN CHRONIC RHINOSINUSITIS (CRS)
PARATEK PHARMACEUTICALS - TOTAL TRANSACTION VALUE OF UP TO $330 MILLION
PARATEK PHARMACEUTICALS- POTENTIAL CONSIDERATION OF UP TO $14 PER SHARE, INCLUDING UPFRONT CONSIDERATION OF $9 PER SHARE